Lilly Nets Another 2nd Circ. Win In Zyprexa MDL

Law360, New York (September 27, 2012, 7:35 PM EDT) -- The Second Circuit on Wednesday affirmed a victory for Eli Lilly & Co. in a suit in multidistrict litigation claiming it failed to warn of diabetes risks associated with its antipsychotic drug Zyprexa, saying a man's physician continued to prescribe the drug after the company sent out warning letters.

In a nonprecedential decision, a three-judge panel upheld a summary judgment ruling in favor of Lilly. The suit was one of a handful remaining in the multidistrict litigation over Zyprexa after the drugmaker paid out $1.2 billion...
To view the full article, register now.

UK Financial Services

UK Financial Services

Read Our Latest UK Financial Services Coverage

Financial Services Law360 UK provides breaking news and analysis on the financial sector. Coverage includes UK and European Union policy, enforcement, and litigation involving banks, asset management firms, and other financial services organizations.